ISO chemical factory,stable supplying, competitive price
*The following content is generated by AI and is for reference only.
Saxagliptin, often associated with research identifiers such as INTS-2 in specific pharmacological databases, is a potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor developed for the management of type 2 diabetes mellitus. Its chemical identity is defined by the molecular formula C17H25N5O3, with a precise molecular weight of approximately 335.4 g/mol. The compound is widely recognized by its CAS Registry Number, 309681-63-6. Structurally, Saxagliptin features a bicyclic pyrrolidine core substituted with a cyanopyrrolidine moiety, which is crucial for its high affinity toward the DPP-4 enzyme.
The primary therapeutic application of Saxagliptin lies in its ability to enhance endogenous incretin levels, specifically glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By inhibiting the enzymatic degradation of these hormones, the drug promotes glucose-dependent insulin secretion from pancreatic beta cells while simultaneously suppressing inappropriate glucagon release from alpha cells. This dual mechanism effectively lowers blood glucose concentrations without inducing significant hypoglycemia when used as monotherapy or in combination with other antidiabetic agents like metformin.
In clinical practice, Saxagliptin is typically administered orally once daily, offering a convenient dosing regimen for patients. It is particularly valuable for individuals who require glycemic control but are at risk for weight gain or hypoglycemia associated with older diabetes therapies. Beyond its established role in metabolic disease, Saxagliptin serves as a critical reference standard in pharmaceutical research for studying DPP-4 inhibition kinetics and exploring novel therapeutic strategies for metabolic disorders. Researchers frequently utilize this compound to investigate the interplay between incretin pathways and cardiovascular health, although recent studies have highlighted specific cardiac safety considerations that necessitate careful patient monitoring. Overall, Saxagliptin represents a significant advancement in the pharmacological landscape of type 2 diabetes, balancing efficacy with a favorable side effect profile for long-term management.